Overcoming Barriers to Immune Therapy in Melanoma

Saturday, November 11

 

8:00 am - 9:00 am Breakfast

 

9:00 am Opening Remarks

Gregory Daniels

 

9:15 am The IKK Complex in the Nexus of Innate

Immunity, Inflammation and Cancer

Michael Karin

 

9:45 am Nuclear Danger Signals as Immune Adjuvants

Davorka Messmer

 

10:15 am Obstruction of T-cell Immunity by Adaptive

Regulatory T-cells

Linda Bradley

 

10:45 am Break

 

11:05 am NKT Cells 'Rev' up the Innate Immune

Response

Mitchell Kronenberg

 

11:35 am Genetic Dissection of the Innate-adaptive

Connection: TLRs and Beyond

Kasper Hoebe

 

12:05 pm Lunch

 

1:00 pm Enhancement of Anti-tumor T-cell Responses

by Cell-associated TLR Ligands

Edith Janssen

 

1:30 pm Monoclonal Antibodies in T-cell Activation

Antoni Ribas

 

2:00 pm CD154 Gene Therapy

Thomas Kipps

 

2:30 pm Galiximab: Targeting the Immunoregulatory

Molecular CD80 in Lymphoma

Steffan Ho

 

3:00 pm Break

 

3:20 pm Treatment of Advanced Malignant Melanoma

with Autologous, Ex Vivo-generated T-cells with

Specificity for Melanoma-associated Target Antigens

Ann Moriarty

 

3:50 pm A Novel Biodegradable Polymer Platform

Technology for Vaccine Delivery

Heather Wilcox

 

4:20 pm Telomerase Vaccination: from Bench to

Bedside

Maurizio Zanetti

 

4:50 pm Closing Remarks and Adjourn